| 2.9876 0 (0%) | 06-09 09:43 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Global Cord Blood Corporation (GCBC), alongside its associated entities, provides specialized services related to umbilical cord blood within the People's Republic of China. The company's operations involve the testing, processing, and long-term storage of cord blood for both private subscribers and donated samples. For the latter, it also facilitates donor matching. As of March 31, 2022, GCBC managed three cord blood banks situated in key regions: Beijing municipality, Guangdong province, and Zhejiang province. The company, which is headquartered in Central, Hong Kong, rebranded as Global Cord Blood Corporation in March 2018, having previously been known as China Cord Blood Corporation. Currently, it functions as a subsidiary under Blue Ocean Structure Investment Company Ltd.
Sat, 12 Sep 2026
Cord Blood Industry Consolidation Escalates in 2026 - BioInformant
Fri, 04 Sep 2026
Global Cord Blood Corp Releases 17th Court Report Detailing Liquidation Progress - Kalkine Media
Thu, 03 Sep 2026
Court liquidators for Global Cord Blood (CORBF) issue 17th report - Stock Titan
Fri, 28 Aug 2026
Stem Cell Umbilical Cord Blood Market Companies, Size & Trends 2026-2035 - precedenceresearch.com
Wed, 12 Aug 2026
Global Cord Blood (CORBF) seeks court approval of third provisional liquidator fee period - Stock Titan
Thu, 23 Jul 2026
Stem Cell Banking Market Size, Growth & Analysis, 2034 - Market Data Forecast
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|